Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Incyte (INCY) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareINCY

Closing price · Nov 19, 2026 $115.96 -1.6% on the day · +14.4% over 12 months 52-week range $90.30 – $129.93
Get INCY alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling8last 12 months
Reported sales$67.8M64 of 64 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 30, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Pablo J. Cagnoni, President sold 1,765 shares at $120.46 ($213K).

Trade date
Nov 16, 2026
Disclosed to the SEC
Nov 18, 2026
Type
Pre-planned sale, 10b5-1 (code S)

Read the original SEC filing ↗All INCY insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

INCY insider transactions (Form 4)

Open-market purchases and sales. 137 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 18SEC Pablo J. CagnoniPresident Sell Plan 1,765183,200 held (−1%) $120.46 $213K -3.7% —
Nov 18SEC Pablo J. CagnoniPresident Sell Plan 877184,965 held (−0%) $121.98 $107K -4.9% —
Nov 18SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 57630,916 held (−2%) $121.98 $70K -4.9% —
Nov 17SEC Lee HeesonEvp, Head Of Incyte Intl Sell Plan 3,70029,333 held (−11%) $120.33 $445K -3.6% —
Nov 17SEC Lee HeesonEvp, Head Of Incyte Intl Sell Plan 2,44926,884 held (−8%) $121.13 $297K -4.3% —
Nov 17SEC Lee HeesonEvp, Head Of Incyte Intl Sell Plan 2,20033,907 held (−6%) $120.44 $265K -3.7% —
Nov 17SEC Lee HeesonEvp, Head Of Incyte Intl Sell Plan 1,47136,107 held (−4%) $121.89 $179K -4.9% —
Nov 17SEC Lee HeesonEvp, Head Of Incyte Intl Sell Plan 87433,033 held (−3%) $121.16 $106K -4.3% —
Nov 10SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 73,96979,492 held (−48%) $119.12 $8.8M -2.7% —
Nov 10SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 60,270153,461 held (−28%) $118.27 $7.1M -2.0% —
Nov 10SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 48,57630,916 held (−61%) $119.66 $5.8M -3.1% —
Nov 10SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 35,042236,067 held (−13%) $116.06 $4.1M -0.1% —
Nov 10SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 22,336213,731 held (−9%) $117.14 $2.6M -1.0% —
Nov 5SEC Thomas TrayPrincipal Accounting Officer Sell Plan 61021,126 held (−3%) $118.96 $73K -2.5% —
Oct 19SEC Pablo J. CagnoniPresident Sell Plan 2,642183,200 held (−1%) $112.71 $298K +2.9% —
Sep 17SEC Pablo J. CagnoniPresident Sell Plan 13,985183,200 held (−7%) $120.49 $1.7M -3.8% —
Sep 17SEC Pablo J. CagnoniPresident Sell Plan 9,233197,185 held (−4%) $120.50 $1.1M -3.8% —
Aug 20SEC Pablo J. CagnoniPresident Sell Plan 10,801183,200 held (−6%) $125.56 $1.4M -7.6% —
Aug 14SEC Pablo J. CagnoniPresident Sell Plan 10,803194,001 held (−5%) $120.04 $1.3M -3.4% —
Aug 7SEC Pablo J. CagnoniPresident Sell Plan 10,640204,804 held (−5%) $122.69 $1.3M -5.5% —
Aug 7SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 2,20761,441 held (−3%) $123.99 $274K -6.5% —
Aug 4SEC Pablo J. CagnoniPresident Sell Plan 15,888215,444 held (−7%) $119.70 $1.9M -3.1% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 14,66188,679 held (−14%) $119.46 $1.8M -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 6,17174,989 held (−8%) $119.43 $737K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 6,05561,441 held (−9%) $120.43 $729K -3.7% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 5,33283,347 held (−6%) $119.42 $637K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 4,69570,294 held (−6%) $119.39 $561K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 2,86467,430 held (−4%) $119.40 $342K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 2,29361,441 held (−4%) $119.41 $274K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 2,18781,160 held (−3%) $119.47 $261K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 1,64365,787 held (−2%) $119.51 $196K -3.0% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 1,64264,145 held (−2%) $119.38 $196K -2.9% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 32663,734 held (−1%) $121.69 $40K -4.7% —
Aug 4SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 8564,060 held (−0%) $122.19 $10K -5.1% —
Jul 20SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 1,87721,118 held (−8%) $114.73 $215K +1.1% —
Jul 20SEC Mohamed Khairie IssaEvp, Head Of U.S. Commercial Sell Plan 1,09363,940 held (−2%) $115.01 $126K +0.8% —
Jul 16SEC Steven H. SteinCmo & Head Of Late-Stage Dev. Sell Plan 28,23726,083 held (−52%) $113.05 $3.2M +2.6% —
Jun 8SEC Thomas TrayPrincipal Accounting Officer Sell Plan 2,63921,132 held (−11%) $100.00 $264K +16.0% —
May 28SEC Thomas TrayPrincipal Accounting Officer Sell Plan 2,05121,132 held (−9%) $97.35 $200K +19.1% —
May 21SEC Paul J. ClancyDirector Sell Plan 15,00023,741 held (−39%) $94.93 $1.4M +22.2% —
Apr 21SEC Pablo J. CagnoniPresident Sell Plan 18,667262,692 held (−7%) $96.50 $1.8M +20.2% —
Mar 19SEC Pablo J. CagnoniPresident Sell Plan 18,667234,800 held (−7%) $94.24 $1.8M +23.0% —
Feb 23SEC Pablo J. CagnoniPresident Sell Plan 18,668234,800 held (−7%) $100.91 $1.9M +14.9% —
Jan 8SEC Mohamed Khairie IssaEvp, Head Of Us Oncology Sell Plan 10,85666,132 held (−14%) $109.07 $1.2M +6.3% —
Jan 7SEC Steven H. SteinEvp & Chief Medical Officer Sell Plan 15,63434,203 held (−31%) $101.70 $1.6M +14.0% —
Dec 22SEC Thomas TrayPrincipal Accounting Officer Sell Plan 2,77422,973 held (−11%) $100.00 $277K +16.0% —
Dec 22SEC Thomas TrayPrincipal Accounting Officer Sell Plan 60022,973 held (−3%) $98.25 $59K +18.0% —
Dec 18SEC Michael James MorrisseyEvp, Head Of Tech. Operations Sell Plan 53,17531,830 held (−63%) $97.29 $5.2M +19.2% —
Dec 18SEC Michael James MorrisseyEvp, Head Of Tech. Operations Sell Plan 4,32327,507 held (−14%) $97.26 $420K +19.2% —
Dec 18SEC Michael James MorrisseyEvp, Head Of Tech. Operations Sell Plan 83385,005 held (−1%) $97.42 $81K +19.0% —
Dec 12SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 5,55360,266 held (−8%) $95.58 $531K +21.3% —
Dec 12SEC Patrick A. MayesEvp & Chief Scientific Officer Sell Plan 25560,011 held (−0%) $94.94 $24K +22.1% —
Dec 3SEC Steven H. SteinEvp & Chief Medical Officer Sell Plan 20,10563,129 held (−24%) $102.51 $2.1M +13.1% —
Dec 3SEC Steven H. SteinEvp & Chief Medical Officer Sell Plan 2,559100,327 held (−2%) $102.96 $263K +12.6% —
Nov 25SEC Thomas TrayPrincipal Accounting Officer Sell Plan 60023,573 held (−2%) $103.00 $62K +12.6% —
Nov 25SEC Thomas TrayPrincipal Accounting Officer Sell Plan 16924,173 held (−1%) $102.00 $17K +13.7% —
Nov 19SEC Sheila A. DentonGeneral Counsel Sell Plan 27826,569 held (−1%) $104.36 $29K +11.1% —
Nov 12SEC Herve HoppenotDirector Sell Plan 187,500329,646 held (−36%) $105.46 $19.8M +10.0% —
Nov 7SEC Steven H. SteinEvp & Chief Medical Officer Sell Plan 5,233102,886 held (−5%) $102.20 $535K +13.5% —
Nov 6SEC Sheila A. DentonGeneral Counsel Sell Plan 59826,569 held (−2%) $101.36 $61K +14.4% —
Nov 5SEC Lee HeesonEvp, Head Of Incyte Intl Sell Plan 3,07429,241 held (−10%) $94.02 $289K +23.3% —
Oct 17SEC Sheila A. DentonGeneral Counsel Sell Plan 27726,569 held (−1%) $85.13 $24K +36.2% —
Oct 6SEC Sheila A. DentonGeneral Counsel Sell Plan 3,50126,569 held (−12%) $85.54 $299K +35.6% —
Oct 6SEC Sheila A. DentonGeneral Counsel Sell Plan 59933,200 held (−2%) $87.65 $53K +32.3% —
Historical context

Similar past setups: not applicable. INCY has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with INCY in the Research Lab

INCY has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

INCY closeInsider buyInsider sale
80100120140DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-02-10EEarnings release filed 2026-04-28EEarnings release filed 2026-07-28EEarnings release filed 2026-10-29Sold $17,238 on 2025-11-21 · Thomas TraySold $24,210 on 2025-12-11 · Patrick A. MayesSold $58,950 on 2025-12-18 · Thomas TraySold $61,800 on 2025-11-24 · Thomas TraySold $72,566 on 2026-11-03 · Thomas TraySold $199,665 on 2026-05-26 · Thomas TraySold $263,475 on 2025-12-01 · Steven H. SteinSold $263,900 on 2026-06-04 · Thomas TraySold $277,400 on 2025-12-19 · Thomas TraySold $297,780 on 2026-10-15 · Pablo J. CagnoniSold $341,054 on 2026-07-16 · Mohamed Khairie Issa, Steven H. SteinSold $389,849 on 2026-11-16 · Pablo J. Cagnoni, Steven H. SteinSold $420,455 on 2025-12-17 · Michael James MorrisseySold $530,756 on 2025-12-10 · Patrick A. MayesSold $729,204 on 2026-08-03 · Patrick A. MayesSold $1,184,064 on 2026-01-07 · Mohamed Khairie IssaSold $1,292,032 on 2026-11-13 · Lee HeesonSold $1,296,792 on 2026-08-12 · Pablo J. CagnoniSold $1,356,174 on 2026-08-19 · Pablo J. CagnoniSold $1,423,950 on 2026-05-19 · Paul J. ClancySold $1,579,068 on 2026-08-05 · Pablo J. Cagnoni, Patrick A. MayesSold $1,589,978 on 2026-01-05 · Steven H. SteinSold $1,759,178 on 2026-03-17 · Pablo J. CagnoniSold $1,801,366 on 2026-04-17 · Pablo J. CagnoniSold $1,883,788 on 2026-02-19 · Pablo J. CagnoniSold $2,060,964 on 2025-12-02 · Steven H. SteinSold $2,797,629 on 2026-09-15 · Pablo J. CagnoniSold $3,192,193 on 2026-07-15 · Steven H. SteinSold $5,254,547 on 2025-12-16 · Michael James MorrisseySold $6,906,966 on 2026-07-31 · Pablo J. Cagnoni, Patrick A. MayesSold $28,435,748 on 2026-11-06 · Steven H. Stein
Bought, 12 months$0
Sold, 12 months$67.8M
Insiders buying0
Insiders selling8

Incyte insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $67.8M of INCY stock on the open market; P/E 263.6 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

INCY insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $30.0M sold (19 trades)Q4 2025Q1 2026: $6.4M sold (4 trades)Q1 2026Q2 2026: $3.7M sold (4 trades)Q2 2026Q3 2026: $18.2M sold (22 trades)Q3 2026Q4 2026: $30.5M sold (15 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$30.5M15
Q3 2026—0$18.2M22
Q2 2026—0$3.7M4
Q1 2026—0$6.4M4
Q4 2025—0$30.0M19

Valuation, profit and volume

P/E (trailing)263.6Sector median 25.0
Volume vs. 50-day0.7×Last 5 sessions

Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Incyte insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $67.8M. Among insiders with enough purchase history to measure, Jean Jacques Bienaime (Director) has the highest Insider Score at 68. 64 of 64 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

INCY earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 29, 2026 +7.6% Sold $298K +3.0%S&P -2.1% pending
Jul 28, 2026 +1.9% Sold $3.5M +6.9%S&P -1.3% -2.1%
Apr 28, 2026 -0.4% Sold $1.8M +3.5%S&P -0.5% -2.4%
Feb 10, 2026 +6.9% None -9.3%S&P -0.3% -6.4%
Oct 28, 2025 +11.1% Sold $376K -3.1%S&P +0.3% +15.8%
Jul 29, 2025 +2.3% None +10.5%S&P -0.4% +9.1%
Apr 29, 2025 +4.7% None +5.3%S&P +0.7% +3.8%
Feb 10, 2025 +2.2% None -10.5%S&P +0.8% +2.1%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

INCY short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 71% of volume sold short2026-08-27: 56% of volume sold short2026-08-28: 72% of volume sold short2026-08-31: 56% of volume sold short2026-09-01: 47% of volume sold short2026-09-02: 48% of volume sold short2026-09-03: 53% of volume sold short2026-09-04: 66% of volume sold short2026-09-08: 46% of volume sold short2026-09-09: 69% of volume sold short2026-09-10: 75% of volume sold short2026-09-11: 68% of volume sold short2026-09-14: 75% of volume sold short2026-09-15: 55% of volume sold short2026-09-16: 70% of volume sold short2026-09-17: 67% of volume sold short2026-09-18: 80% of volume sold short2026-09-21: 66% of volume sold short2026-09-22: 63% of volume sold short2026-09-23: 53% of volume sold short2026-09-24: 64% of volume sold short2026-09-25: 70% of volume sold short2026-09-28: 61% of volume sold short2026-09-29: 72% of volume sold short2026-09-30: 67% of volume sold short2026-10-01: 64% of volume sold short2026-10-02: 71% of volume sold short2026-10-05: 64% of volume sold short2026-10-06: 81% of volume sold short2026-10-07: 77% of volume sold short2026-10-08: 64% of volume sold short2026-10-09: 68% of volume sold short2026-10-12: 62% of volume sold short2026-10-13: 78% of volume sold short2026-10-14: 71% of volume sold short2026-10-15: 68% of volume sold short2026-10-16: 72% of volume sold short2026-10-19: 59% of volume sold short2026-10-20: 72% of volume sold short2026-10-21: 78% of volume sold short2026-10-22: 87% of volume sold short2026-10-23: 83% of volume sold short2026-10-26: 74% of volume sold short2026-10-27: 78% of volume sold short2026-10-28: 79% of volume sold short2026-10-29: 85% of volume sold short2026-10-30: 81% of volume sold short2026-11-02: 58% of volume sold short2026-11-03: 61% of volume sold short2026-11-04: 49% of volume sold short2026-11-05: 54% of volume sold short2026-11-06: 54% of volume sold short2026-11-09: 51% of volume sold short2026-11-10: 47% of volume sold short2026-11-11: 67% of volume sold short2026-11-12: 65% of volume sold short2026-11-13: 61% of volume sold short2026-11-16: 60% of volume sold short2026-11-17: 76% of volume sold short2026-11-18: 57% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 57%20-day average: 69%Prior 2 months: 67%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Insiders at Incyte

InsiderBoughtSoldLast filingPast buys beat S&PScore
Steven H. SteinCmo & Head Of Late-Stage Dev. — $36.4M Nov 18, 2026 — —
Herve HoppenotDirector — $19.8M Dec 10, 2025 — —
Pablo J. CagnoniPresident — $14.7M Nov 18, 2026 — —
Patrick A. MayesEvp & Chief Scientific Officer — $6.6M Aug 7, 2026 — —
Michael James MorrisseyEvp, Head Of Tech. Operations — $5.7M Feb 4, 2026 — —
Lee HeesonEvp, Head Of Incyte Intl — $1.6M Nov 17, 2026 — —
Paul J. ClancyDirector — $1.4M Oct 2, 2026 — —
Mohamed Khairie IssaEvp, Head Of U.S. Commercial — $1.3M Jul 20, 2026 — —
Thomas TrayPrincipal Accounting Officer — $952K Nov 5, 2026 — —
Sheila A. DentonGeneral Counsel — $465K Nov 19, 2025 — —
Edmund HarriganDirector — — Oct 2, 2026 — —
Baker Bros. Advisors LPDirector — — Oct 2, 2026 — —
David H. GardnerEvp, Chief Strategy Officer — — Sep 24, 2026 — —
Ramitpal K. BasiEvp, Human Resources — — Aug 27, 2026 — —
William MeuryCEO — — Jul 20, 2026 — —
Richard A. HoffmanGeneral Counsel — — Jul 20, 2026 — —
Otis W. BrawleyDirector — — Jun 10, 2026 0 of 1 —
Jean Jacques BienaimeDirector — — Jun 10, 2026 2 of 2 68
Jacqualyn A. FouseDirector — — Jun 10, 2026 — —
Katherine A. HighDirector — — Jun 10, 2026 — —
Suketu UpadhyayCFO — — May 6, 2026 — —
Matteo TrottaEvp, Gm, Dermatology Us — — Mar 26, 2026 — —

Board links: companies that share insiders with INCY

Directors and executives who filed Form 4s for INCY and another company in the last 12 months.

See the map →
  • AAgilent Technologies Otis W. Brawley Director here · Director at A · latest filing Jun 10, 2026
  • ASNDAscendis Pharma A/S Jean Jacques Bienaime Director here · Director at ASND · latest filing Aug 18, 2026
  • IMNMImmunome Jean Jacques Bienaime Director here · Director at IMNM · latest filing Jun 10, 2026
  • KROSKeros Therapeutics Jean Jacques Bienaime Director here · Director at KROS · latest filing Aug 19, 2026
  • VRTXVertex Pharmaceuticals Suketu Upadhyay CFO here · Director at VRTX · latest filing May 6, 2026
  • ZBHZimmer Biomet Suketu Upadhyay CFO here · CFO at ZBH · latest filing May 6, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

INCY stock: common questions

Are Incyte insiders buying INCY stock?

No. No Incyte insider reported an open-market purchase of INCY in the past 12 months.

Are Incyte insiders selling INCY stock?

8 insiders reported sales worth $67.8M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is INCY's P/E ratio?

INCY trades at about 263.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is INCY's 52-week range?

Over the past year INCY has traded between $90.30 and $129.93. It last closed at $115.96 on Nov 19, 2026.